February 1, 2005 A company that proposes to make a reality of personalized medicine, Favrille uses a patient’s own tumor to develop an immunotherapy for indolent B-cell non-Hodgkin’s lymphoma (NHL), an incurable, inevitably fatal disease. Their lead drug candidate, FavId is currently in Phase III trials for NHL. We look at the company’s science and its finances on the eve (more or less) of its IPO...
